Cite
HARVARD Citation
Hui, R. et al. (n.d.). 289PDLucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. Annals of oncology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Hui, R. et al. (n.d.). 289PDLucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. Annals of oncology. p. . [Online].